Bayer is committed to the advancement of science supporting the lifesaving and preventive benefits of Aspirin and improved outcomes in cardiovascular disease, diabetes, and other conditions. Aspirin is one of the most extensively studied drugs in history. To date, more than 200,000 patients have been studied in more than 200 randomized clinical trials evaluating Aspirin efficacy and safety.

To learn about studies of Aspirin in the prevention of initial cardiovascular events or ongoing clinical research studies involving Aspirin, click below.

Aspirin Studies in Primary Prevention | Ongoing Aspirin Studies